# A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)

> **NCT01077544** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 15 (actual)

## Conditions studied

- Chronic Myeloid Leukemia
- Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** Nilotinib

## Key facts

- **NCT ID:** NCT01077544
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-04-14
- **Primary completion:** 2015-07-01
- **Final completion:** 2015-07-01
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2020-12-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01077544

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01077544, "A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01077544. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*